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Abstract: Microcalcifications are an early mammographic sign of breast 
cancer and a target for stereotactic breast needle biopsy. We present here a 
Raman spectroscopic tool for detecting microcalcifications in breast tissue 
based on their chemical composition. We collected ex vivo Raman spectra 
from 159 tissue sites in fresh stereotactic breast needle biopsies from 33 
patients, including 54 normal sites, 75 lesions with microcalcifications and 
30 lesions without microcalcifications. Application of our Raman technique 
resulted in a positive predictive value of 97% for detecting 
microcalcifications. This study shows that Raman spectroscopy has the 
potential to detect microcalcifications during stereotactic breast core 
biopsies and provide real-time feedback to radiologists, thus reducing non-
diagnostic and false negative biopsies. 
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1. Introduction 
Breast cancer is the second leading cause of cancer death in women, with one in eight women 
likely to develop breast cancer in her lifetime. In the United States alone 254,650 new cases 
of breast cancer occurred in 2010 [1]. The exact cause of breast cancer is still under debate 
although breast cancer surgery and treatment have been extensively studied. However, the 
most effective approach for preventing  morbidity and mortality is early detection. X-ray 
mammography is currently the only accepted routine screening method for early detection of 
breast cancer [2]. Microcalcifications geographically target the most clinically significant 
abnormality within the breast and are considered an early mammographic sign of breast 
cancer [3]. They are currently graded radiographically as typically benign, of intermediate 
concern or of higher probability of malignancy, based on their size, shape, number, roughness 
and degree of clustering [4]. Microcalcifications can also be divided into two types based on 
their chemical composition and histopathologic appearance in breast biopsy tissue: type I 
microcalcifications composed of calcium oxalate (CAO) crystals; and type II 
microcalcifications composed of calcium phosphate concretions, mainly calcium hydroxyapatite (CHA). Microcalcification type also correlates with disease state [5]. Type I 
microcalcifications are seen almost exclusively in benign duct cysts and are rarely found in 
foci of breast cancer, while type II microcalcifications are most often seen in proliferative 
lesions, including invasive and in situ cancer. While microcalcifications can be detected by x-
ray mammography, this procedure cannot distinguish type I and II microcalcifications based 
on their chemical composition. Thus, a tissue biopsy must be performed to determine whether 
the microcalcifications are associated with cancer. 
Currently, most patients undergo vacuum-assisted stereotactic core needle biopsy for 
microcalcifications. Despite stereotactic guidance, recent studies have documented the failure 
to retrieve microcalcifications in up to 15% of these biopsies [6]. Failure to retrieve the 
microcalcifications results in non-diagnostic or false negative biopsies, requiring the patient to 
undergo repeat biopsy, often as a surgical procedure. Therefore, there is a clinical need for a 
tool that can detect microcalcifications in the tissue to be biopsied and provide real-time 
feedback to the radiologist during stereotactic biopsies as to whether the microcalcifications 
seen on mammography will be retrieved. 
As a non-destructive, chemical-specific technique, Raman spectroscopy is particularly 
amenable to in vivo studies and an ideal choice for detecting microcalcifications during breast 
core needle biopsies. In this process, incident photons transfer energy to and from the 
molecular vibrational and/or rotational modes of chemical species in the tissue, giving rise to 
shifts in the energy of the emitted photons. Since the energy level is unique for each such 
vibrational/rotational mode of the molecule, these Raman shifts provide fingerprint details on 
the chemical composition of the tissue. 
Raman spectroscopy has been successfully applied to the study of calcifications in various 
organ systems, including kidney and other urinary tract stones [7], atherosclerotic plaque [8–
10] and calcified heart valves [11,12]. There are several groups currently studying breast 
microcalcifications using Raman spectroscopy [13–16]. Previously we have explored Raman 
spectroscopy [17–22] and other minimally invasive spectroscopic optical techniques for the 
diagnosis of breast cancer [23]. Our group was the first to demonstrate the potential of Raman 
spectroscopy to detect and distinguish type I and II microcalcifications and to differentiate 
type II calcifications associated with benign and malignant breast lesions [13], in Raman 
microscopy studies of formalin-fixed, paraffin-embedded breast biopsies. Baker et al in 2010 
confirmed these findings in studies of breast microcalcifications using FTIR spectroscopy 
[16]. 
In this work, we present for the first time ex vivo  studies for real-time detection of 
microcalcifications in core needle breast biopsy specimens using Raman spectroscopy. Raman 
spectra were collected from freshly excised tissue from 33 patients undergoing stereotactic 
core needle breast biopsy procedures and fit to our previously developed model of breast 
chemical and morphological components to determine quantitatively the contribution of each 
component to the measured Raman spectrum. We then developed algorithms to detect the 
presence of microcalcifications in the breast tissue based on model fit coefficients (FC) for 
total calcium (CAH plus CAO), collagen and fat. In addition to detecting microcalcifications, 
this technique could also be used to distinguish type I from type II microcalcifications. This 
technique has the potential to detect and classify microcalcifications, even smaller than those 
detected by radiology, in real-time, and thus to guide core needle biopsy procedures with the 
goal of reducing non-diagnostic and false negative biopsies. 
2. Instrument 
The portable, compact clinical Raman spectroscopy system (instrument and optical fiber 
probes) used in these studies was developed at the Laser Biomedical Research Center at the 
Massachusetts Institute of Technology (MIT). The instrument delivers excitation light from 
an 830 nm InGaAs diode laser (Process Instruments, Salt Lake City, UT) to the tissue via an 
optical fiber probe, which is in the form of a flexible catheter with a total length of about 4m and diameter of approximately 2 mm, previously described in detail [24]. The probe consists 
of a single excitation fiber surrounded by nine collection fibers, each with a diameter of 200 
µm. The excitation fiber terminates in a short-pass filter centered at 830 nm which transmits 
the laser excitation light while blocking the fiber background (i.e. the Raman and fluorescence 
signal generated by the excitation fiber). The fiber is gently brought into contact with the 
tissue in a light tight black box while collecting data. The Raman signal is collected using the 
nine collection fibers which terminate in a long pass filter to suppress the elastically scattered 
light emanating from the tissue. This filter transmits the tissue Raman scattered light while 
effectively rejecting any undesirable fiber background that may have been caused by the high 
intensity elastic scattering component. The distal end of the probe has a sapphire ball lens 
which focuses the excitation light onto the tissue and efficiently collects the scattered light 
from the tissue into the collection fibers. The linear array of collection fibers at the proximal 
end of the fiber is coupled to a spectrograph for dispersion onto a back illuminated, deep 
depletion, thermoelectrically-cooled CCD detector (PIXIS 256, 26x26μm pixels, 1024x256 
array, Princeton Instruments). Laser power was 98-105 mW. The Raman spectra were 
acquired by vertical binning prior to averaging 10 successive frames, each with an acquisition 
time of 0.25 s, for a total collection time of 2.5 s. The data is analyzed in real-time, with the 
fitting algorithm taking another 1.8 s to generate the FC and render a diagnosis using a FC-
based decision algorithm. The whole process is automated and takes less than 5 s per 
measurement point. 
3. Data analysis 
The instrument was calibrated daily prior to data collection. For wavenumber calibration, 
spectra from 4-acetamidophenol (Tylenol) with known Raman peak positions are collected. 
To correct the Raman spectra for the system wavelength response, light is collected from a 
wavelength-calibrated tungsten halogen lamp diffusely scattered from a reflectance standard, 
barium sulfate (BaSO4). To get rid of the probe background, spectra are collected from a 
roughened aluminum surface. Different weightings of the aluminum spectra are subtracted, 
choosing the optimal one depending on the tissue optical properties. To remove background 
fluorescence, the data is fitted with a sixth order polynomial and subtracted from the raw data. 
The software stores these calibration spectra, which allows real-time data analysis and display 
of the calibrated Raman spectra and model fits and, thus, assessment of the quality of the 
Raman spectroscopic data acquired. This allows Raman data to be re-collected from the same 
spot if, for example, the CCD is saturated as it was on initial spectral acquisition for 6 tissue 
sites. In these instances, the data was collected again by averaging 20 frames, each with an 
acquisition time of 0.125 sec, maintaining a total collection time of 2.5 sec. 
Once the Raman spectra are acquired, they are fit with a breast model we developed [18], 
in which the Raman tissue spectrum is considered a linear combination of its constituent basis 
spectra, Pi, and their concentrations, Ci, at wavenumber ω (Eq. (1)): 
  () .() ii Sw CPw =∑    (1) 
The model includes basis spectra for epithelial cell nuclei, epithelial cell cytoplasm, fat 
cells, cholesterol-like extracellular deposits, beta-carotene, stromal collagen fibers, type I 
microcalcifications (calcium oxalate) and type II microcalcifications (largely calcium 
hydroxyapatite). 
Ordinary least squares fitting is used to find the contribution of each basis spectrum to the 
observed spectrum by minimizing the sum of squared residuals, where the residual represents 
the difference between the acquired spectrum and the fitted value provided by our model. The 
main advantage of this process is that it yields FC that correlate with the presence or absence 
of spectral contributions from the basis spectra, providing information about the 
morphological and chemical composition of the tissue. The goodness of the fit is qualitatively estimated from visual inspection of the residual after fit and quantitatively from the standard 
deviation of the residual. Specifically, a Raman spectrum is eliminated from analysis if the 
standard deviation of the residual is greater than 0.2 (as this results in a poor model fit) or if it 
is determined to be an outlier using a Student's t-test assessment of the Mahalanobis 
distance(s) as detailed in the Results section. 
4. Patient population and tissue preparation 
Breast tissue was obtained from 33 patients (all female; ages 38-79) undergoing vacuum-
assisted stereotactic core needle breast biopsy procedures in the Breast Health Center at 
University Hospitals-Case Medical Center. All studies were approved by the Case Cancer 
Institutional Review Board and the Massachusetts Institute of Technology Committee On the 
Use of Humans as Experimental Subjects. Informed consent was obtained from all subjects 
prior to their biopsy procedures. 
All data were collected from freshly excised biopsy specimens in a room just outside the 
biopsy suite within 30 minutes of excision. The tissue cores collected during the needle 
biopsy procedure were placed inside a Petri dish moistened with normal saline and were 
typically of approximate dimension 1.7mm × 2.0 cm, due to the geometry of the needle. A 
tissue core of interest was then selected by identifying a focus of microcalcifications within 
the core on the specimen radiograph. The selected core was then placed on an Aluminum 
block inside a light-tight black box for data collection. Spectra were collected from several 
tissue sites of interest on each core (typically a focus of microcalcifications, a lesion (grossly 
abnormal tissue) without microcalcifications and normal tissue) identified again by 
comparison with the specimen radiograph. Spectra were also collected from different cores in 
each biopsy, so the number of spectra varied from patient to patient. Real time data analysis 
was used to help confirm data collection from tissue sites with microcalcifications. After 
spectral acquisition, the sites interrogated spectroscopically on the tissue cores were marked 
with multicolored colloidal inks to uniquely identify each tissue site. The tissue was then 
fixed in 10% neutral buffered formalin, routinely processed, paraffin embedded, cut into 
tissue sections and stained with hematoxylin and eosin (H&E). The tissue cores were oriented 
at embedding and the cut tissue sections mounted on the glass slides so that the colored ink 
spots marking the sites interrogated spectroscopically were visible on microscopic 
examination, for comparison of histopathology and spectroscopy results. A specimen 
radiograph of a biopsy tissue core with microcalcifications and corresponding histopathology 
photomicrograph illustrating the overlying colored ink spot are shown in Fig. 1. The H&E 
stained tissue sections are next examined by an experienced breast pathologist. Both the 
radiographic appearance based on the specimen radiograph and the histopathology diagnosis 
were considered as gold standards for comparison to the spectroscopic results. Breast lesions  
 
 
Fig. 1. (a)  Radiography and (b) histopathology of breast biopsy tissue site with type II 
microcalcifications. The microcalcifications are seen as small white densities (white arrow) in 
the specimen radiography in (a), and as blue concretions (red arrows) in the photomicrograph 
in (b) (H&E; 4X), which shows black ink (black arrows) marking  the site interrogated 
spectroscopically. were classified as having microcalcifications in two ways. First, lesions were classified based 
on the radiographic appearance alone, if microcalcifications were seen at that tissue site on the 
specimen radiograph, as these are the lesions targeted by the radiologist for biopsy. And 
second, based on the radiographic appearance plus histopathology, if microcalcifications were 
seen at that tissue site either on the specimen radiograph or on the H&E stained tissue 
sections. This was done because microcalcifications were seen on the H&E stained tissue 
sections at 13 sites that were not seen on the specimen radiograph [25]. 
5. Results 
Raman spectra were collected from 228 breast biopsy tissue sites. The signal-to-noise rates 
(SNR) of the Raman spectra varied based on the histopathology category, with diseased tissue 
exhibiting a lower SNR than normal tissue due to higher fluorescence. Never-the-less, the 
model fits were reasonably good for both normal and diseased tissues. Figures 2a and 2b 
show typical Raman spectra of normal breast tissue and a breast lesion (fibrocystic change) 
with type II microcalcifications, with model fits and residuals. A prominent band at 960 cm
−1 
due to hydroxyapatite (arrow) is present in the Raman spectrum of the lesion with 
microcalcifications. 
The Raman spectrum of only 1 tissue site was excluded from data analysis due to poor 
SNR that resulted in a poor model fit. Raman spectra of 9 tissue sites were excluded as 
spectral outliers using a Student’s t-test employing a Mahalanobis distance function (95% 
probability;  p<0.05) [26,27]. Raman spectra of 38 tissue sites were excluded because a 
histopathology diagnosis could not be rendered as the corresponding ink spots were not seen 
on the H&E stained tissue sections due to improper paraffin embedding of the biopsy. Three 
additional tissue sites were eliminated from data analysis due to contamination of the tissue 
core with an unidentified birefringent foreign material seen on the H&E stained tissue 
sections. The radiographic appearance was uncertain for 18 tissue sites and these were also 
excluded. Therefore, the final data set consisted of Raman spectra from 159 tissue sites. The 
159 tissue sites were classified as follows based on the radiographic appearance: 54 normal, 
75 lesions with microcalcifications, and 30 lesions without microcalcifications. Based on 
radiography plus histopathology, the tissue sites were classified as follows: 51 normal, 88 
lesions with microcalcifications, and 20 lesions without microcalcifications. Table 1 details 
the histopathology diagnoses of the breast lesions with and without microcalcifications, which 
included fibrocystic change, fibroadenoma, ductal carcinoma in situ and invasive ductal 
carcinoma. 
 
Fig. 2. Typical Raman spectra of (a) normal breast tissue  and (b) breast lesion (fibrocystic 
change) with type II microcalcifications, with model fits and residuals. A prominent band at 
960 cm-1 due to hydroxyapatite (arrow) is present in the Raman spectrum of the lesion with 
microcalcifications. Table 1. Histopathology Diagnoses of Breast Tissue Sites classified by Radiography plus 
Histopathology 
Lesion 











Carcinoma  Other*  Total 
Normal  51  0  0  0  0  0  51 
Lesions with 
microcalcifications 
4  49  17  13  1  4  88 
Lesions without 
microcalcifications 
0  18  0  1  1  0  20 
*Other, fat necrosis or healing biopsy site. 
Seventy-four of the 88 lesions classified as lesions with microcalcifications on 
radiography plus histopathology had microcalcifications confirmed on histopathology, 14 did 
not. Seventy had type II and only 4 had type I microcalcifications. Some lesions with 
microcalcifications contained only a single microcalcification; others contained greater than 
25 microcalcifications. Individual microcalcifications ranged from 10 to 1030 µm in diameter 
(mean 218 µm). The microcalcifications were 0-2150 µm deep in the tissue cores (distant 
from the probe-tissue interface), which ranged from 1075 to 2850 µm in maximum thickness. 
5.1. Detection of breast lesions with microcalcifications 
Raman spectra collected from all 159 tissue sites were analyzed for the FC of CAH, CAO and 
total calcium (CAH + CAO), as well as the other Raman active model constituents present in 
the breast tissue. We visualized the spread in the FCs for all of the model constituents using 
box plots. Boxplots of the FC of total calcium for breast lesions classified by radiographic 
appearance alone and by radiography plus histopathology are shown in Fig. 3. The box plots 
are a graphical representation of the data, in which the lower limit and upper limit of the box 
represent the first and third quartiles, and the center line representing the second quartile 
(median). The extreme values are defined by values which exceed or are below the median by 
more than 1.5 times the interquartile range. Data points outside of this range are defined as 
outliers and indicated by crosses. From the box plot shown in Figs. 3a and 3b it is clearly 
evident  that normal tissue, lesions with microcalcifications and lesions without 
microcalcifications can be easily distinguished based on total calcium content. 
Based on the results of the boxplot analysis, we devised an empirical Raman spectral 
algorithm to detect breast lesions with microcalcifications based on the FC of total calcium.  
 
 
Fig. 3. Box plots of the distribution of FC for total calcium for breast tissue sites classified by 
(a) radiographic appearance alone and (b) radiography plus histopathology  (MC, 
microcalcifications).  
Fig. 4. Empirical Raman algorithm using decision threshold of FC total calcium = 11 for 
detection of breast lesions with microcalcifications, classified by (a) radiographic appearance 
alone  and (b) radiography plus histopathology. 
The performance of the algorithm varied with different threshold FC values of total calcium. 
We selected the threshold FC for total calcium of 11 in order to maximize the positive 
predictive value (PPV), which is the most clinically significant measure  of algorithm 
performance for the intended clinical application (Figs. 4a and 4b). With this decision 
threshold value, the algorithm yielded a PPV of 89% for the detection of lesions with 
microcalcifications, with a negative predictive value (NPV) of 86%, sensitivity (SE) of 84%, 
specificity (SP) of 86% and overall accuracy of 87%, when the tissue sites are classified by 
radiographic appearance alone. Performance of the algorithm improves significantly to a PPV 
of 97%, with an NPV of 78%, SE of 77%, SP of 97% and overall accuracy of 89%, when the 
tissue sites are classified by radiography plus histopathology. Using this decision threshold, 
we were able to detect microcalcifications as small as 10 µm and as deep as 2150 µm from 
the probe-tissue interface. 
We  next devised a Raman spectral algorithm to detect breast lesions with 
microcalcifications using logistic regression, a discriminate analysis technique, which we 
used to correlate the FC with the diagnostic categories for all combinations of the 12 
components in the model (plus total calcium), and determine the probability thresholds that 
correctly classified the most tissue sites [20]. A likelihood ratio test was used to determine the 
fit coefficients most significant for diagnosis, which are: CAH, CAO, fat and collagen. The 
optimal algorithm (Fig. 5) was based on three parameters, total calcium, collagen, and fat, and 
defined by the following plane equation (Eq. (2)): 
  0.2371 0.4755 ( ) – 0.0507 0.0787 0 CAO CAH Fat Collagen FC FC FC FC + ∗ + ∗− ∗ =    (2) 
where FCCAO, FCCAH, FCFat  and FCCollagen  are the model fit coefficients for CAO, CAH, 
collagen and fat, resp. This logistic regression algorithm yielded a PPV of 96%, NPV of 85%, 
SE of 86%, SP of 96% and overall accuracy of 91%, when the tissue sites are classified by 
radiography plus histopathology. (These numbers were obtained by employing the logistic 
regression algorithm on the training data set itself, i.e. auto-prediction.) The PPV and SP of 
this algorithm (96% and 96%, resp.) are comparable to those of the empirical algorithm (97% 
and 97%), but there is significant improvement in NPV and SE (85% and 86%, resp.) 
compared to those of the empirical algorithm (78% and 77%, resp.). 
Subsequently, the logistic regression Raman algorithm was also validated using a 
traditional leave-one-out cross validation technique [20]. In this technique, the data from a 
particular tissue site is eliminated, and logistic regression is used to form a decision line that 
classifies the remaining tissue sites optimizing agreement with the histopathology diagnoses.  
  
Fig. 5. Logistic regression Raman algorithm distinguishing lesions with microcalcifications 
(red squares) from normals + lesions without microcalcifications (blue circles), classified by 
radiography plus histopathology. 
The resulting decision threshold is then used to classify the excluded site. This process is 
successively applied to each of the sites. Leave-one-out cross validation yielded a PPV of 
95%, NPV of 85%, SE of 86%, SP of 94% and overall accuracy of 90%. Only one additional 
tissue site was misclassified (as compared to the aforementioned autoprediction case), shifting 
from a true negative to a false positive. Since cross-validation is widely accepted to be a good 
indicator of the quality of modeling (in contrast to autoprediction which may force an 
unrealistically optimistic answer on a system), the cross-validation results obtained here 
provide a high level of confidence in the viability of this approach and its outlook for true 
prospective application. A comparison of the performance of the empirical and logistic 
regression algorithms and leave-one-out cross validation is shown in Table 2. 
Table 2. Comparison of Performance of Raman Algorithms for Detecting Breast Lesions 
with Microcalcifications, with Tissue Sites Classified using Radiography plus 
Histopathology 
Raman Algorithm  PPV (%)  NPV (%)  SE (%)  SP (%)  Overall Accuracy (%) 
Empirical  97  78  77  97  89 
Logistic Regression  96  85  86  96  91 
Cross Validation  95  85  86  94  90 
5.2. Distinction of type I and type II microcalcifications 
As a chemically sensitive technique, Raman spectroscopy also has the potential to distinguish 
type I and type II microcalcifications based on the presence or absence of vibrational intensity 
at specific wavenumbers. In this study, microcalcifications in 4 of 74 lesions with 
microcalcifications were type I. The spectra of these breast lesions were characterized by the 
presence of Raman bands at 912 cm
−1 and 1477 cm-1 (Fig. 6a), characteristic of calcium 
oxalate (Fig. 6b). In contrast, Raman spectra of the 70 lesions with type II microcalcifications 
on histopathology were dominated by a Raman band at 960 cm
_1 (Fig. 6c), characteristic of 
calcium hydroxyapatite (Fig. 6d). These results show that Raman spectroscopy has the 
potential to not only detect microcalcifications, but also distinguish  type I and type II 
microcalcifications. Because very few type I microcalcifications are present in the data set, a 
spectral algorithm to distinguish type I and II microcalcifications was not developed.  
Fig. 6. Typical Raman spectra and histopathology of breast lesions (fibrocystic change) with 
type I and II microcalcifications. The Raman spectrum of the breast lesion with type I 
microcalcifications in (a) shows prominent bands at 912 cm-1 and 1477 cm-1 (arrows) 
characteristic of calcium oxalate; the calcium oxalate crystals comprising the type I 
microcalcifications (b) do not bind H&E (left panel) and appear as colorless crystals (arrows) 
that are birefringent when viewed under polarized light (right panel). In contrast, the Raman 
spectrum of the breast lesion with type II microcalcifications in (c) shows a prominent band at 
960 cm_1 (arrow) characteristic of calcium hydroxyapatite; the calcium hydroxyapatite rich 
type II microcalcifications appear as basophilic concretions on the H&E stain (d) and are non-
birefringent. 
6. Discussion 
The results of this study demonstrate that Raman spectroscopy has the potential to both detect 
microcalcifications, and potentially distinguish type I and type II microcalcifications, in tissue 
cores obtained during stereotactic breast needle biopsies. We initially classified the tissue sites 
based on the radiographic appearance, as the lesions targeted by the radiologist for biopsy are 
identified radiographically. Using a Raman algorithm with a total calcium FC decision 
threshold = 11, all normal tissue sites were correctly identified as negative for 
microcalcifications. When the tissue sites were classified based on the radiographic 
appearance alone, there were only 8 false positives, that is breast lesions without radiographic 
microcalcifications that were diagnosed by the Raman algorithm as having 
microcalcifications. Interestingly, 4 of these breast lesions had microcalcifications on 
histopathology, suggesting that the Raman diagnosis was in fact correct for these lesions. 
Because of this finding, we also classified the tissue sites using radiography plus 
histopathology, so that lesions with histologic microcalcifications not seen by radiography 
would also be classified as lesions with microcalcifications. In this case, the number of false 
positives decreased to 2 for the empirical algorithm and 3 for the logistic regression 
algorithm. The 4 tissue sites with microcalcifications seen only on histopathology were correctly diagnosed by both Raman algorithms as having microcalcifications. The average 
size of the microcalcifications seen on histopathology for these 4 lesions was 65 µm (average 
depth (distance from the probe-tissue interface) 575 µm), which is smaller than can be 
detected on mammography (detection limit 100 µm) [25],  suggesting that at the selected 
decision threshold our Raman technique is more sensitive to the presence of 
microcalcifications than mammography. The most likely explanation for the remaining false 
positives is histopathology sampling error [28], although  additional H&E stained tissue 
sections were examined in an effort to find microcalcifications in these tissue sites. 
This Raman technology is being developed to guide the radiologist during stereotactic 
core needle biopsy procedures to retrieve the target  tissue with microcalcifications for 
pathology diagnosis. PPV is the most important measure of algorithm performance for this 
clinical application, because false positive results represent a greater risk to the patient than 
false negative results [29]. If the results of the Raman algorithm indicate that the tissue to be 
biopsied harbors a microcalcification when it does not, the radiologist may retrieve only that 
one tissue core and thus miss the target microcalcification. In this case, the biopsy may be 
non-diagnostic or false negative and the patient may have to undergo a second stereotactic or 
surgical biopsy. On the other hand, if the results of the Raman algorithm indicate that the 
tissue to be biopsied does not harbor a microcalcification when it does, the radiologist may 
retrieve additional tissue cores that were not needed. While undesirable, this does not 
represent a significant risk to the patient. 
Our empirical Raman algorithm was based on the FC of total calcium as it must detect 
both CAO-rich type I and CAH-rich type II microcalcifications. It detected breast lesions with 
microcalcifications with a PPV of 89% when the tissue sites were classified by radiographic 
appearance and 97% when the tissue sites were classified by radiography plus histopathology, 
reflecting its sensitivity to microcalcifications seen on histopathology that were not seen on 
radiography. The PPV was comparable (96%) for the logistic regression algorithm based on 
the FC of total calcium, fat and collagen, again when the tissue sites were classified by 
radiography plus histopathology. In addition, there was significant improvement in NPV and 
SE (85% and 86%, resp.) compared to those of the empirical algorithm (78% and 77%, resp.). 
Therefore, the logistic regression algorithm appears more robust. This is not surprising since 
the algorithm employs not only the FC for CAH and CAO found in the microcalcifications 
themselves (as total calcium), but also the FC for fat and collagen. Using the logistic 
regression algorithm, in order for a tissue site to be classified as a lesion with 
microcalcifications, it must have not only increased total calcium (FC CAH + FC CAO) but 
also an increased FC for collagen and a decreased FC of fat. This reflects the increase in 
collagen-rich stroma at the expense of fat cells seen in the breast lesions associated with 
microcalcifications, including fibrocystic change, fibroadenoma, ductal carcinoma in situ and 
invasive ductal carcinoma. Interestingly, the FC for fat and collagen are the key diagnostic 
parameters in our previously devised Raman algorithm to distinguish breast cancer from 
benign breast lesions such as fibrocystic change and fibroadenoma in the absence of 
microcalcifications [20,22]. Leave-one-out cross validation yielded only one additional 
misclassification, indicating that the logistic regression framework is not overfitting the 
acquired data set. This in turn suggests that the logistic regression algorithm can be applied 
successfully for prospective predictions in larger scale clinical studies, as it is more likely to 
be generalizable for larger data sets than the empirical algorithm. 
One surprising result was the detection of microcalcifications up to 2150 µm deep in the 
breast biopsy tissue cores (distant from the probe-tissue interface). Previous studies have 
suggested a penetration depth of only ~1mm (1000 µm) for Raman spectroscopy using our 
optical fiber probe [17]. There are several possible explanations for the apparent deeper tissue 
penetration depth. One is that the target microcalcifications are highly active Raman scatterers 
and thus may be detectable with fewer effective photons at greater depths than less Raman 
active breast constituents. Second, our optical fiber probe makes use of separate excitation and collection fibers. Thus there is a small (800 µm) source-detector separation, which may 
also increase penetration depth. Tissue simulating phantom studies by Stone and associates 
have shown that microcalcifications can be detected to a depth of 8.7 mm depth using 
spatially offset Raman spectroscopy (SORS), in which Raman signals are collected from a 
region of interest that is spatially offset from the point of illumination on the sample surface 
(by 2cm in their studies) [15]. Therefore it is not unreasonable to suggest that we can detect 
microcalcifications at depths greater than 1mm. 
7. Conclusion 
We present here a Raman spectroscopic tool for detection of microcalcifications in breast 
tissue obtained during stereotactic breast core biopsies, based on their chemical composition. 
Application of our optimal, logistic regression-derived Raman diagnostic algorithm resulted 
in a PPV of 96% for detecting microcalcifications. This study shows that Raman spectroscopy 
has the potential to detect microcalcifications at stereotactic breast core biopsy and provide 
real-time feedback to radiologists, reducing non-diagnostic and false negative biopsies. 
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